Cardiogenic Shock Clinical Trial
— LEVO-ECMOOfficial title:
Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study
Failure of Weaning from ECMO is a serious complication, reaching an incidence between 29 and 58%. Inotrops are frequently used to help separating patient from ECMO. Levosimendan is an ino-dilatatory medication and was used in different clinical settings. The aim of this study was to evaluate the benefit with levosimendan when used in weaning process.
| Status | Recruiting |
| Enrollment | 65 |
| Est. completion date | January 2019 |
| Est. primary completion date | January 2019 |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Age over 18 - Patient requiring the need for short-term assistance - Patient who has agreed to use his medical data for research purposes Exclusion Criteria: - Refusal to participate in the study - Non-weaning attempts due to a death under assistance or a relay by a long-term assistance or heart transplant - Non-cardiac indications of assistance (indication of pulmonary replacement) - Subject under guardianship or curatorship |
| Country | Name | City | State |
|---|---|---|---|
| France | Service Réanimation chirurgicale cardiovasculaire-NHC | Strasbourg |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Strasbourg, France |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Comparison of the incidence of weaning failure between patients with levosimendan and others | Data were recorded from admission until 48 hours after weaning from ECMO |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03283995 -
Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
|
||
| Active, not recruiting |
NCT04325035 -
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
|
Phase 2 | |
| Active, not recruiting |
NCT05100836 -
SURPASS Impella 5.5 Study
|
||
| Not yet recruiting |
NCT05106491 -
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
|
N/A | |
| Completed |
NCT02301819 -
ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock
|
N/A | |
| Completed |
NCT01367743 -
Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock
|
Phase 4 | |
| Recruiting |
NCT05728359 -
Genomic Determinants of Outcome in Cardiogenic Shock
|
||
| Recruiting |
NCT05699005 -
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO
|
Phase 1 | |
| Not yet recruiting |
NCT06338345 -
Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients
|
N/A | |
| Completed |
NCT03436641 -
Microcirculation in Cardiogenic Shock
|
||
| Recruiting |
NCT03313687 -
SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
|
||
| Recruiting |
NCT05506449 -
The RECOVER IV Trial
|
N/A | |
| Completed |
NCT04144660 -
"Treatment Use of ECMO In Pregnancy or Peripartum Patient."
|
||
| Completed |
NCT04548739 -
Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
|
||
| Recruiting |
NCT04141410 -
Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
|
||
| Not yet recruiting |
NCT05879276 -
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
|
Phase 3 | |
| Enrolling by invitation |
NCT05570864 -
Score TO Predict SHOCK - STOP SHOCK
|
||
| Completed |
NCT02591771 -
Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock
|
Phase 2 | |
| Terminated |
NCT02279979 -
Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial
|
N/A | |
| Completed |
NCT01374867 -
CardShock Study and Registry
|
N/A |